Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials
<p><strong>Background</strong> The ChAdOx1 nCoV-19 (AZD1222) vaccine has been approved for emergency use by the UK regulatory authority, Medicines and Healthcare products Regulatory Agency, with a regimen of two standard doses given with an interval of 4–12 weeks. The planned roll-...
Hlavní autoři: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Další autoři: | |
Médium: | Journal article |
Jazyk: | English |
Vydáno: |
Elsevier
2021
|